Additionally, Yadong Fan et al., 2021 investigated the anti-inflammatory activity of Tongmai Yangxin pill, a formula including PM, in treatment of coronary heart disease, and results showed that TMYX treatment showed reduced levels of apolipoprotein B, endothelin 1, nuclear factor κB (NF-κB) and homocysteine in CHD patients, suggesting the formula’s effectiveness in attenuating macrophage foam cell formation and its anti-inflammatory activity through modulation of the ESR1 and NF-κB signaling pathways. Here, APOB is linked to coronary artery disorder.